On Wednesday, Shares of Canadian Pacific Railway Limited (USA) (NYSE:CP), lost -1.50% to $140.85.
Canadian Pacific Railway Limited, accomplished the sale to Norfolk Southern Corp. (NS) of more than 280 miles of track from Schenectady, N.Y., to Sunbury, Pa.
The US$214.5 million sale (subject to adjustments) of the Delaware & Hudson South (D&H) was first declared November 14, 2014 and approved by the U.S. Surface Transportation Board on May 15, 2015.
The D&H South sale comprises all branch lines and industrial spurs that connect to the Sunbury-Schenectady main line, plus some equipment, vehicles and parts. CP will formally cease rail operations on the corridor this evening.
About 45,000 CP carloads and shipping containers move across the line annually, counting consumer goods, salt, grain and forest products.
Canadian Pacific Railway Limited, through its auxiliaries, operates a transcontinental railway in Canada and the United States. The company provides logistics and supply chain expertise services.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), declined -4.12% to $93.30, during its last trading session.
Alnylam Pharmaceuticals, declared initial positive results from its ongoing Phase 1 clinical trial with ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. The Phase 1 study is being performed in asymptomatic “high excreter” (ASHE) patients, who carry the genetic mutation of acute intermittent porphyria (AIP) and have elevated levels of aminolevulinic acid (ALA) and porphobilinogen (PBG), the toxic heme intermediates that mediate porphyria attacks. Study results showed that single subcutaneous doses of ALN-AS1 resulted in an up to 82% lowering of ALA and an up to 93% lowering of PBG, providing human proof-of-concept for this investigational RNAi therapeutic as a potential therapy for AIP and other acute hepatic porphyrias. In addition, through analysis of exosomal mRNA preparations from serum and urine, it was demonstrated that ALN-AS1 treatment resulted in potent, dose-dependent, and durable silencing of ALAS1 mRNA in liver. Further, ALN-AS1 was found to be generally well tolerated with no clinically noteworthydrug-related adverse events to date. The company has now transitioned to Part B of the Phase 1 study, in which subjects are receiving monthly subcutaneous dosing, and the company anticipates to initiate Part C in AIP patients suffering from recurrent attacks in early 2016. In addition, Alnylam presented initial data from the EXPLORE trial, a multinational, prospective observational study of patients with hepatic porphyrias suffering from recurrent attacks.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs comprise Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia.
At the end of Wednesday’s trade, Shares of Barnes & Noble, Inc. (NYSE:BKS), lost -1.66% to $13.07.
Barnes & Noble, declared that it will celebrate all things Batman at its stores nationwide on “Batman Day,” Saturday, September 26. Batman Day is back by popular demand from DC Entertainment, and to honor one of the world’s most popular Super Heroes and global pop-culture icons, Barnes & Noble will offer customers 20% off a selection of the most in-demand Batman graphic novels and DVDs throughout the day. The offer comprises graphic novels like Batman: The Killing Joke by Alan Moore, Batgirl Vol. 1: The Batgirl of Burnside (The New 52) by Brenden Fletcher, Batman: The Dark Knight Returns by Frank Miller, and so much more, plus DVDs counting The Dark Knight, The Dark Knight Rises, Batman Starts, Batman Returns, and others.
Plus, Barnes & Noble customers will get a free Batman Endgame Special Edition #1 comic book with a Barnes & Noble exclusive variant cover, while supplies last, also available on NOOK®. Customers can enter for a chance to win up to three exclusive Batman Day prints by Sean Murphy that will be given away in stores nationwide. Customers should contact their local store for details.
Barnes & Noble, Inc. retails books, textbooks, magazines, newspapers, and other contents in the United States. It sells trade books, counting hardcover and paperback consumer titles; mass market paperbacks, such as mystery, romance, science fiction, and other fiction; children’s books; eBooks and other digital content; textbooks and course-related materials; NOOK and related accessories; bargain books; gifts; emblematic apparel and gifts; school and dorm supplies; café products and services; educational toys and games; and music and movies.
Finally, EarthLink Holdings Corp. (NASDAQ:ELNK), ended its last trade with -0.72% loss, and closed at $8.23.
EarthLink Holdings and IRONMAN, declared a multi-year partnership during which EarthLink will serve as the Official Technology Partner of the IRONMAN U.S. Series. From WiFi to safeguarding payments and tracking athlete progress, IRONMAN will leverage EarthLink’s technology services and expertise to enhance the event experience for its entire community of athletes, families and spectators.
As part of the partnership, EarthLink will review race experiences and work with IRONMAN to implement technology and network changes that will improve athlete tracking, event communications, and data security. The aim is to ensure that the entire IRONMAN community will benefit from these enhancements, counting athletes, spectators, remotely located friends and family members, and on-site IRONMAN Village exhibitors.
EarthLink Holdings Corp., together with its auxiliaries, provides managed network, security, and cloud services to business and residential customers in the United States. The company operates in two segments, Business Services and Consumer Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
